EPS for Olin (OLN) Expected At $0.16, Cytrx (CYTR) Sentiment Is 1.38

July 17, 2017 - By Nellie Frank

CytRx Corporation is a biopharmaceutical research and development firm specializing in oncology. The company has market cap of $87.47 million. The Firm is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It currently has negative earnings. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma whose tumors have progressed after treatment with chemotherapy.

Analysts expect Olin Corporation (NYSE:OLN) to report $0.16 EPS on July, 31 after the close.They anticipate $0.08 EPS change or 33.33% from last quarter’s $0.24 EPS. OLN’s profit would be $26.96M giving it 49.14 P/E if the $0.16 EPS is correct. After having $0.14 EPS previously, Olin Corporation’s analysts see 14.29% EPS growth. About 252,027 shares traded. Olin Corporation (NYSE:OLN) has risen 51.90% since July 17, 2016 and is uptrending. It has outperformed by 35.20% the S&P500.

Sabby Management Llc holds 0.1% of its portfolio in CytRx Corporation for 4.70 million shares. Alliancebernstein L.P. owns 34,700 shares or 0% of their US portfolio. Moreover, Amalgamated Bank has 0% invested in the company for 11,924 shares. The New York-based American International Group Inc has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 20,326 shares.

About 1.27M shares traded. CytRx Corporation (CYTR) has declined 78.08% since July 17, 2016 and is downtrending. It has underperformed by 94.78% the S&P500.

Among 9 analysts covering Olin Corporation (NYSE:OLN), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Olin Corporation had 26 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Friday, July 22 with “Outperform”. The stock has “Buy” rating by Cowen & Co on Wednesday, June 28. The stock of Olin Corporation (NYSE:OLN) has “Neutral” rating given on Wednesday, September 2 by UBS. The stock has “Sector Perform” rating by RBC Capital Markets on Tuesday, September 8. The firm has “Buy” rating by Nomura given on Thursday, January 7. Cowen & Co maintained Olin Corporation (NYSE:OLN) on Monday, September 21 with “Market Perform” rating. UBS maintained the shares of OLN in report on Tuesday, November 3 with “Neutral” rating. The firm earned “Outperform” rating on Monday, June 13 by RBC Capital Markets. The stock has “Outperform” rating by Cowen & Co on Friday, February 10. The rating was upgraded by Monness Crespi to “Buy” on Thursday, February 4.

Since February 6, 2017, it had 0 insider purchases, and 7 insider sales for $2.78 million activity. PAIN GEORGE H sold 60,000 shares worth $1.82 million. BUNCH C ROBERT sold 10,000 shares worth $296,500. Curley Stephen C sold $176,311 worth of stock. MCINTOSH JOHN L also sold $37,950 worth of Olin Corporation (NYSE:OLN) shares. On Wednesday, March 1 the insider OKeefe Thomas J sold $322,642.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: